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Postoperative analgesia with the oral compounds utilized
was good, no significant differences being shown between the
two preparations. Side-effects were minimal and acceptable,
and it is evident that patients can be changed to this type of
oral analgesia within 12 - 24 hours of the operative procedure.
Smoking does not appear to produce any serious side-effects,
either deleterious or beneficial.
The objective of effective management of postoperative pain
should be to provide optimal pain relief with minimal danger,
side-effects and adverse reactions. Currently there does nor
appear to be an analgesic agent or technique which offers
clearly superior advantages over all others so that it can be
recommended unequivocally.
Dr S. G. Reinach of the Institute for Biostatistics of the South
African Medical Research Council, Johannesburg, performed the
statistical analyses. We should like to thank our many colleagues
for allowing this study to be performed on patients in their care,
in particular Dr C. J. T. Craig. Thanks are also due to the Chief
Medical Superintendent of Groote Schuur Hospital, Dr H.-Reeve
Sanders, for permission to publish.
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Low plasma pyridoxal-5'-phosphate levels
in children with the nephrotic syndrome
A.J. VAN BUUREN, G. S. SHEPHARD, D. LABADARIOS
Summary
Of 35 children with the nephrotic syndrome in
relapse. 88% were found to have low circulating
plasma pyridoxal-5' -phosphate (PLP) levels. Remis-
sion of the syndrome was assocrated with spon-
taneous normalization of plasma PLP levels in 23
such children. A significant (P < 0.001) positive
correlation (r = 0.81) was found between plasma
albumin and PLP levels and a significant (P < 0,001)
negative correlation (r = -0.66) between plasma PLP
and serum cholesterol levels. The low plasma PLP
levels may be due to enhanced urinary excretion of
albumin-bound PLP in view of the severe proteinuria
which characterizes the nephrotic syndrome.
S Aft Med J 1985; 61: 329-332.
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The active co-enzyme form of vitamin B6, pyridoxal-S'-phos-
phate (PLP), is considered to be a good index of vitamin B6
nutriture,I-J and on this basis biochemical deficiencies have
been reported in a variety of clinical conditions. I-7 In particular,
biochemical vitamin B6 deficiency has been documented in
chronic renal failure 8.' with enhanced degradation of PLP
proposed as the underlying mechanism. 10.11 Similar explanations
have been proposed for the deficiency documented in patients
with liver disease.6.12.13
Although some extensive work has been done on the require-
ments of vitamins in chronic renal failure, and in haemodialysed
patients in particular,14 the vitamin requirements in other
renal conditions such as the nephrotic or nephritic syndromes
are unknown. We report on vitamin B6 nutrition in children
with the nephrotic syndrome.
Patients and methods
Forty-eight children who had either previously had or at the
time of the study were suffering from active nephrotic syn-
drome were studied. The criteria used for inclusion in the
study were: (I) heavy proteinuria (> 2 g/m2/d); (ii) hypo-
albuminaemia « 30 g/l); and (iil) hypercholesterolaemia.
Nine of these children were studied in both relapse and
remission (no proteinuria), 26 were studied in relapse and 13
in remission alone, giving a total of 35 studied in relapse and
22 in remission. There were 29 boys and 19 girls. Six of the
children were white and 42 of various ethnic origin; their ages
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Fig. 2. Plasma PLP levels in normal controls and children with
th~ nephrotic syndrome in remission and relapse.
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Fig. 1. Mean plasma albumin concentration in normal controls
and children with the nephrotic syndrome in remission and
relapse.
Results
varied from 1Y2 years to 15 Y2 years with a mean age of 7 years
(median 6 years 11 months).
As part of their assessment renal needle-biopsy specimens
were taken under direct fluoroscopy from 38 children. In I
case consent for the biopsy procedure was refused. The histo-
logical classification was as follows: 12 cases of membranous
nephropathy (all hepatitis B-associated), 4 mesangiocapiIlary
glomerulonephritis, 3 endocapillary glomerulonephritis, 15
varying degrees of mesangial proliferative glomerulonephritis
with or without mesangial matrix thickening, 1 focal segmental
glomerulosclerosis, and 3 minimal-change disease (MeD).
The remaining children who did not undergo renal biopsy
procedures were presumed to have MCD because of their
previous or subsequent satisfactory response to corticosteroids.
There were therefore 11 cases of MCD. Children with MCD
tended to have selective proteinuria whereas those with other
histological findings had non-selective proteinuria.
Treatment was essentially supportive in those children re-
quiring hospitalization during the study (27 patients). This
included a high-protein (4 g/kg), low-salt diet as well as
intravenous 20% low-salt human albumin and diuretics as
necessary. No vitamin supplements were administered before
or during the study period. Four children who had initially
been studied in relapse were studied in remission after steroid
therapy. TO cytostatic agents were used during the study.
Mild prerenal uraemia was evident in several children in the
acute nephrotic phase. Supportive therapy in those children
studied as outpatients could not be monitored.
Forty-one healthy children with normal renal function
attending follow-up outpatient clinics served as controls; there
were 24 boys and 17 girls and none had proteinuria. Three
children were white and 38 were of various ethnic origins,
their ages ranged from 6 months to 15 years 10 months with a
mean of 9 years 6 months (median 9 years 8 months). None of
these children was on vitamin supplementation before or
during the study.
The protocol for the study was approved by the Ethics
Committee of the University of Stellenbosch. Informed consent
in respect of the extra 5 ml of blood drawn by venepuncture
over and above that required for the children's evaluation was
obtained from their parents. Plasma albumin levels were deter-
mined by protein electrophoresis and serum cholesterol and
creatinine levels by the Technicon sequential multiple analyser
computer system. Plasma PLP was determined by the tyrosine
apodecarboxylase method. IS Serial determinations of PLP,
albumin, cholesterol and creatinine levels were determined
whenever possible (necessary), in which case the average of
such determinations was taken both in relapse and in remission
or in the control group. The analysis of variance was used for
the statistical evaluation of all the results obtained.
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The mean plasma albumin concentration (± SE) (Fig. 1) in
children with the nephrotic syndrome (18,2 ± 1,1 g/l) was
significantly (P < 0,001) lower than in normal controls (41,4 ±
0,5 g/l) and children in remission (38,5 ± 1,0 g/l). The mean
plasma albumin concentration was also significantly lower
(P < 0,05) in children in remission than in normal controls.
Similarly, the mean plasma PLP concentration (Fig. 2) was
significantly (P < 0,001) lower in children with L'le nephrotic
syndrome (3,9 ± 0,3 ng/ml) than in normal controls (10,8 ±
1,0 ng/ml) and children in remission (11,5 ± 0,7 nglml). The
difference in mean plasma PLP in normal controls and children
in remission was not significant. Thus a significant (P < 0,001)
positive correlation (r = 0,81) existed between plasma albumin
and PLP levels in these patients (Fig. 3). As expected, the
mean serum cholesterol concentration (10,3 ± 0,7 mmol/l)
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Fig. 3. Correlation between plasma albumin and PLP levels in
children with the nephrotic syndrome in relapse and remission. Fig. 5. Correlation between serum cholesterol and plasma PLP
levels in children with the nephrotic syndrome in relapse and
remission.
Fig. 4. Serum cholesterol concentration in normal controls and
children with the nephrotic syndrome in remission and relapse.
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was significantly (P < 0,00 I) higher in the patients in relapse
than in normal controls (4,0 ± 0,18 mmol/l) and children in
remission (4,5 ± 0,3 mmol/I) (Fig. 4). Furthermore, a signifi-
cant (P < 0,001) negative correlation (r = -0,69) existed
between serum choleste~ol and plasma PLP levels (Fig. 5).
Sequential determinations of plasma albumin and PLP levels
during the course of the illness in 4 typical patients are
presented in Fig. 6.
Fig. 6. Sequential plasma albumin and PLP levels in 4 typical
patients during the course of their illness.
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Discussion
Our findings have shown for the first time that, regardless of
the aetiology of the nephrotic syndrome, 88% of patients in
relapse have low circulating plasma levels of PLP. A positive
significant correlation was obtained between plasma levels of
PLP and albumin and a negative one between plasma PLP
and serum cholesterol levels. Remission of the syndrome was
associated with spontaneous normalization of plasma PLP
levels in all the patients studied.
The underlying mechanism of the low plasma PLP levels is
not at present clear. PLP, the main circulating vitamer in
blood, is known to be 'almost totally' bound to albumin. 3 The
nephrotic syndrome is characterized by massive proteinuria,
either selective (mainly albumin) or non-selective (albumin +
other proteins), generally depending on whether the nephrotic
syndrome is due to MeD or not. It would therefore appear
that increased urinary excretion of PLP in the albumin-bound
form may be responsible for the low PLP levels documented
in our patients. This postulate would be consistent with the
spontaneous normalization of plasma PLP levels upon remis-
sion. The imponance of proteinuria is funher substantiated by
the normal plasma PLP levels in the children in remission, in
whom the plasma albumin level was significantly lower than
that of normal controls, which may be due to the fact that the
patients were sampled too early in remission. A similar
mechanism has been proposed for other protein-bound
materials, such as calcium and vitamin D and its vitamers,16
which are reponed to be low in patients with the nephrotic
syndrome. Alternatively, and in view of the documented
malabsorption of cenain nutrients 17 such as ea2+ in patients
with the nephrotic syndrome, the absorption of vitamin B6
may be impaired in these patients.
Although plasma PLP is considered to be a reliable index of
vitamin B6 nutrition,IB it is not clear whether the low plasma
PLP levels reported in the present study indicate vitamin B6
deficiency in these patients, panicularly in view of the hypo-
albuminaemia and proteinuria which characterize the nephrotic
syndrome. However, in view of the imponant role of vitamin
B6 in intermediary metabolism, prophylactic administration of
vitamin B6 supplements in the management of these patients
would appear to be desirable.
We thank Mrs M. Huisman for technical assistance, and the
children and their parents whose consent made the srudy possible.
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